PEARL Trial Results: What a Year of Low-Dose Rapamycin Actually Showed
A year-long, placebo-controlled rapamycin trial in healthy older adults missed its main goal. What it did find, especially in women, is smaller, stranger and more useful than the hype.
It was past eleven, the house quiet, and I was reading a study abstract on my phone with the brightness turned down. The drug was rapamycin, which has made mice live longer, tested for a full year in healthy older people. I caught myself scanning for one sentence: yes, it works, here are your extra good years.
That sentence wasn't there. What was there took a second reading, in daylight, to see properly.
Software work left me with a habit I can't shake. When a build comes back, I read the failing test first, because the red one usually tells you more than all the green ones put together. PEARL has a red test right at the top of its results, and that is where I want to start.
This is not medical advice. One small trial does not justify starting rapamycin, and if you are curious about it for yourself, that conversation belongs with a physician who knows your history.
What PEARL Was, and What It Measured
PEARL was a double-blind, randomized, placebo-controlled trial of rapamycin in healthy adults aged 50 to 85. It ran for 48 weeks and has been described as the longest study so far of rapamycin for healthy aging. The results appeared in April 2025 in the journal Aging.
It was also decentralized. Participants were recruited through AgelessRx, a telehealth longevity company, and most of the trial happened at a distance: virtual check-ins, blood draws at local Quest or LabCorp sites, and body scans at partner facilities.
Of 125 people who enrolled, 114 finished: 40 on 5 mg once a week, 35 on 10 mg once a week, and 39 on placebo. About 35 percent were women, and in the 10 mg group, only one in five. Hold on to that number.
The primary endpoint was visceral fat, the deep abdominal fat packed around the organs, measured by DXA, the low-dose X-ray scan used for bone density. Those scans also tracked lean tissue mass, a rough stand-in for muscle, and bone mineral content and density. Alongside them came safety blood panels, the SF-36 questionnaire on things like pain, general health and emotional well-being, and an epigenetic age test in a small subset.
One detail about the drug changes how you read the rest. PEARL used compounded rapamycin, and partway through, the team found it reached only about one-third the blood concentration of commercial sirolimus. So 10 mg of the compounded drug was roughly equal to 3.33 mg of generic sirolimus. The label promised more than the bloodstream received.
What It Found, Starting With the Miss
The red test first. Visceral fat did not change on rapamycin compared with placebo (p = 0.942, about as flat as a result gets). The trial missed its primary endpoint.
The authors name fair reasons. Participants were health-conscious with low starting body fat, the cohort was small, adherence was self-reported, and real drug exposure was lower than planned. None of that turns a miss into a hit. It only tells you the question is still open.
Bone didn't move either. The scans showed no significant change in bone mineral content or density.
Then the secondary signals:
- Women on 10 mg gained lean tissue mass at 24 weeks (p = 0.043) and 48 weeks (p = 0.018). Men did not.
- Women on 10 mg reported less pain at 24 weeks (p = 0.011) and 48 weeks (p < 0.001).
- The 5 mg group reported better general health at 24 and 48 weeks.
- Emotional well-being improved at 48 weeks in the 5 mg group (p = 0.047), and also in the placebo group (p = 0.025).
That last line deserves a pause. People on a dummy pill felt emotionally better too, by a statistically significant margin, which shows how far hope and attention alone can move a questionnaire. It is worth remembering when you read the pain result.
Blood markers stayed within normal ranges, with small shifts such as more red blood cells in the 5 mg group. Epigenetic age, tested in only 24 people, showed no meaningful change, and men on 10 mg had more gut dysbiosis, an imbalance in gut bacteria.
Safety looked reassuring. Adverse and serious adverse events were similar across groups, with placebo actually recording the most serious ones. Gastrointestinal symptoms were more common on rapamycin (eight cases on 10 mg, seven on 5 mg, four on placebo), and one person on 5 mg developed anemia, was treated, and finished the trial.
Reassuring, with an asterisk: one year, 114 health-conscious people, and exposures lower than the labels say. It tells us little about higher doses, longer use or less healthy bodies.
The Finding in Women, and What Might Explain It
This is the part that made me sit up in bed. More lean mass and less pain, in the same women on the higher dose, reads like a coherent story about a sturdier old age.
Now read the failing test again. Women were one in five of the 10 mg group, so these results rest on fewer than ten people. The trial also compared many outcomes across doses, sexes and time points, and the more comparisons you run, the more likely a few cross the significance line by chance. That doesn't make the finding false. It makes it the kind of result that needs a larger trial built around it.
If it is real, why women? PEARL wasn't built to answer that, but a few questions seem worth holding:
- Drug levels. In the National Institute on Aging's Interventions Testing Program, rapamycin extended lifespan more in female mice than in males at each dose tested, and the females had higher blood levels of the drug, which the researchers suggested might partly explain it. Whether that applies to people is unknown.
- Dose per body. A fixed weekly dose may simply be a larger dose for a smaller body. That is a question, not a finding.
- Life stage. Would the effect differ depending on where a woman is relative to menopause? The trial did not look at this.
- Chance. The least exciting explanation, and with numbers this small, a live one.
The authors acknowledge that women were underrepresented, and the trial's one body-composition effect turned up in the group it had the fewest of.
Why Off-Label Rapamycin Use Keeps Rising Anyway
If the human data are this thin, why is off-label prescribing growing through longevity clinics and telehealth services? I don't think the answer is foolishness. The mouse evidence is genuinely strong, including longer lives when rapamycin was started late. The mechanism is tidy too: rapamycin inhibits mTOR, a nutrient-sensing pathway that helps tell cells when to grow, and dialing down a growth signal feels intuitively right for aging, though nobody has shown that in people.
The dosing feels careful as well. At daily doses rapamycin is an immunosuppressant used in organ transplantation, with known side effects such as mouth sores, raised blood lipids and glucose changes. Longevity prescribers use intermittent weekly low doses to try to limit those. And a trial proving longer healthy human life would take many years, which feels like forever when you are 60 and well.
I recognize the pull in myself. With a young child at home, a quiet arithmetic runs in the background: how many good years, how much strength, whether I'll still get down on the floor to play. A pill that promises more of those years has a pull no p-value fully cancels. We just don't know yet whether it delivers.
How This Differs From the Metformin Conversation
Rapamycin and metformin often get mentioned in the same breath, but they sit in different places.
Metformin is a cheap, off-patent diabetes drug. The trial meant to test it against aging, TAME (Targeting Aging with Metformin), is designed for more than 3,000 people aged 65 to 79 over six years, asking whether metformin delays age-related chronic diseases such as heart disease, cancer and dementia. As of 2026, the American Federation for Aging Research still lists TAME as awaiting funding and not launched. Its low price is part of why a trial that size is hard to fund.
PEARL asked a smaller, earlier question: is this reasonably safe for a year, and does anything measurable shift? In engineering terms, it checked that a new component doesn't crash the system, which is a long way from proving it makes the system better. Rapamycin also carries a particular worry, immune suppression at daily doses, which is why so much of its conversation is about dose and schedule.
The metformin story is waiting for a large trial to begin. The rapamycin story has started small, and its longest trial so far came back mostly quiet, with one intriguing whisper.
A Plain-Language Scorecard: What We Know and What We Don't
Here is how I'd sum it up for a friend at the kitchen table. It is no substitute for your doctor.
| Question | Where it stands | What that means |
|---|---|---|
| Does rapamycin extend lifespan in mice? | Known | Yes, in the NIA testing program, even when started late in life. |
| Does it extend healthy life in people? | Unknown | No human trial has shown this. |
| Is weekly low-dose use safe for a year? | Early reassurance | Adverse events similar to placebo, more stomach upset, one small trial. |
| Does it cut visceral fat or help bone? | Not shown | No significant change in PEARL. |
| Does it add lean mass or ease pain in women? | A hint | Fewer than ten women on the higher dose. It needs its own trial. |
| What is the right dose? | Unknown | Compounded versions may deliver far less than the label says. |
| What about daily, higher doses? | Known risks | Immune suppression, mouth sores, raised lipids and glucose changes. |
Read down the middle column. The solid evidence lives in mice and in high-dose risks, while almost everything a healthy person wants to know sits in the unknown and hint rows.
Frequently Asked Questions
Should I start taking rapamycin because of PEARL? No. One small trial that missed its primary endpoint does not justify starting a drug that suppresses the immune system at higher doses. If you are curious, talk it through with a physician who knows your history and your medications.
Did PEARL show that rapamycin slows aging? No. It measured body composition, blood work and questionnaires, and epigenetic age did not meaningfully change in the 24 people tested.
Why does the compounding issue matter? The dose on the bottle was not the dose in the blood. Both the reassuring safety data and the flat results apply to exposures about a third of what the same dose of commercial sirolimus would give.
Is 5 mg or 10 mg the better weekly dose? PEARL cannot tell you. Different outcomes moved in different groups, which is common with small samples and many measurements, and neither dose changed the primary endpoint.
When I went back to that abstract in daylight, the failing test was still at the top, and I had stopped wanting it gone. It is the most honest line in the report. An open question, held honestly, is better company for whatever years we get than an answer borrowed from mice.